In Vitro Antifungal and Antibacterial Activities of Pentacycloundecane Tetra-Amines

Chemical Biology and Drug Design

Volumn 77, Issue 4, 2011, Pages 295-299

  Onajole, Oluseye K ^a   Coovadia, Yacoob ^b   Govender, Thavendran ^a   Kruger, Hendrik G ^a   Maguire, Glenn E M ^a   Naidu, Dianithi ^b   Singh, Nisha ^a   Govender, Patrick ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b INKOSI ALBERT LUTHULI CENTRAL HOSPITAL   (South Africa)

Author keywords

Antibacterial; Antifungal; Pentacycloundecane; Polycyclic 'cage'

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; NITROBLUE TETRAZOLIUM; PENTACYCLOUNDECANE TETRA AMINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; BACILLUS SUBTILIS; BROTH DILUTION; CANDIDA ALBICANS; COLORIMETRY; CONTROLLED STUDY; ELIZABETHKINGIA MENINGOSEPTICA; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FUNGAL STRAIN; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHODOCOCCUS EQUI; SPOROTHRIX SCHENCKII; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS XYLOSUS; STREPTOCOCCUS AGALACTIAE;

ALKANES; AMINES; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; BACTERIA; CYCLIZATION; FUNGI; MICROBIAL SENSITIVITY TESTS;

CANDIDA ALBICANS; ELIZABETHKINGIA MENINGOSEPTICA; ESCHERICHIA COLI; FUNGI; NEGIBACTERIA; POSIBACTERIA; SPOROTHRIX SCHENCKII; TETRA;

EID: 79952615763     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01055.x     Document Type: Letter

References (32)

1. Singh N. (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis;33:1692-1696.
2. Sun H.Y., Singh N. (2008) Emerging importance of infections due to zygomycetes in organ transplant recipients. Int J Antimicrob Agents;32:S115-S118.
3. Netsvyetayeva I., Swoboda-Kopec E., Paczek L., Fiedor P., Sikora M., Jaworska-Zaremba M., Blachnio S., Luczak M. (2009) Trichosporon asahii as a prospective pathogen in solid organ transplant recipients. Mycoses;52:263-265.
4. Fidel P.L., Vazquez J.A., Sobel J.D. (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev;12:80-96.
5. Walsh T.J., Groll A.H. (1999) Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis;1:247-261.
6. Eckmanns T., Ruden H., Gastmeier P. (2006) The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis;193:1408-1418.
7. Singh N., Avery R.K., Munoz P., Pruett T.L., Alexander B., Jacobs R., Tollemar J.G., Dominguez E.A., Yu C.M., Paterson D.L., Husain S., Kusne S., Linden P. (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis;36:46-52.
8. Castroagudin J.F., Ponton C., Bustamante M., Otero E., Martinez J., Tome S., Conde R., Segade F.R., Delgado M., Brage A., Galban C., Varo E. (2005) Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transpl Proc;37:3965-3967.
9. Powderly W.G., Kobayashi G.S., Herzig G.P., Medoff G. (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med;84:826.
10. Rex J.H., Cooper C.R., Merz W.G., Galgiani J.N., Anaissie E.J. (1995) Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother;39:906-909.
11. Geldenhuys W.J., Malan S.F., Bloomquist J.R., Marchand A.P., Van der Schyf C.J. (2005) Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med Res Rev;25:21-48.
12. Nagasawa H.T., Elberling J.A., Shirota F.N. (1973) 2-Aminoadamantane-2-carboxylic acid, a rigid, achiral, tricyclic alpha-amino-acid with transport inhibitory properties. J Med Chem;16:823-826.
13. Zah J., Terre'Blanche G., Erasmus E., Malan S.F. (2003) Physicochemical prediction of a brain-blood distribution profile in polycyclic amines. Bioorg Med Chem;11:3569-3578.
14. Brookes K.B., Hickmott P.W., Jutle K.K., Schreyer C.A. (1992) Introduction of pharmacophoric groups into polycyclic systems 4. aziridine, oxiran, and tertiary beta-hydroxyethylamine derivatives of adamantane. S Afr J Chem;45:8-11.
15. Ito F.M., Petroni J.M., de Lima D.P., Beatriz A., Marques M.R., de Moraes M.O., Costa-Lotufo L.V., Montnegro R.C., Magalhaes H.I.F., Pessoa C.D.O. (2007) Synthesis and biological evaluation of rigid polycyclic derivatives of the Diels-Alder adduct tricyclo[6.2.1.0(2, 7)]undeca-4-9-dien-3, 6-dione. Molecules;12:271-282.
16. Orzeszko A., Kaminska B., Starosciak B.J. (2002) Synthesis and antimicrobial activity of new adamantane derivatives III. Farmaco;57:619-624.
17. Kolocouris A., Dimas K., Pannecouque C., Witvrouw M., Foscolos G.B., Stamatiou G., Fytas G., Zoidis G., Kolocouris N., Andrei G., Snoeck R., De Clercq E. (2002) New 2-(1-adamantylcarbonyl)-pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation. Bioorg Med Chem Lett;12:723-727.
18. Orzeszko B., Kazimierczuk Z., Maurin J.K., Laudy A.E., Starosciak B.J., Vilpo J., Vilpo L., Balzarini J., Orzeszko A. (2004) Novel adamantylated pyrimidines and their preliminary biological evaluations. Farmaco;59:929-937.
19. Papakonstantinou-Garoufalias S., Pouli N., Marakos P., Chytyroglou-Ladas A. (2002) Synthesis antimicrobial and antifungal activity of some new 3-substituted derivatives of 4-(2, 4-dichlorophenyl)-5-adamantyl-1H-1, 2, 4-triazole. Farmaco;57:973-977.
20. Kadi A.A., El-Brollosy N.R., Al-Deeb O.A., Habib E.E., Ibrahim T.M., El-Emam A.A. (2007) Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1, 3, 4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1, 3, 4-thiadiazoles. Eur J Med Chem;42:235-242.
21. Orzeszko A., Gralewska R., Starosciak B.J., Kazimierczuk Z. (2000) Synthesis and antimicrobial activity of new adamantane derivatives I. Acta Biochim Pol;47:87-94.
22. Orzeszko A., Kaminska B., Orzeszko G., Starosciak B.J. (2000) Synthesis and antimicrobial activity of new adamantane derivatives II. Farmaco;55:619-623.
23. Protopopova M., Hanrahan C., Nikonenko B., Samala R., Chen P., Gearhart J., Einck L., Nacy C.A. (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J Antimicrob Chemother;56:968-974.
24. SQ109 (2008) SQ109. Tuberculosis (Edinb) 88, 159-161.
25. Onajole O.K., Govender K., Govender P., Van Helden P., Kruger H.G., Maguire G.E.M., Muthusamy K., Pillay M., Wiid I., Govender T. (2009) Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent ant-tuberculosis agents. Eur J Med Chem;44:4297-4305.
26. NCCLS (2002) Clinical and Laboratory Standards Institute. Referencee method for broth dilution antifungal susceptibility testing of yeasts, approved standard M27-A2, vol. 22, no. 15, 2nd edn, CLSI Document. Clinical and Laboratory Standards Institute, Villanova, PA, 2002. 22.
27. CLSI (2008) Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard M38-A, vol. 22, no. 16, Clinical and Laboratory Standards Institute, Wayne, PA, 2002. 22.
28. Promega (2005) CellTiter 96 AQueous one solution cell proliferation assay. Technical Bulletin.
29. Schwalbe R., Steele-Moore L., Goodwin A.C. (2007) Antimicrobial Susceptibility Testing Protocols, Vol. 1. CRC Press, New York, NY, USA.
30. Eloff J.N. (1998) A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria. Planta Med;64:711-713.
31. Hawser S.P., Norris H., Jessup C.J., Ghannoum M.A. (1998) Comparison of a 2, 3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) colorimetric method with the Standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol;36:1450-1452.
32. Meletiadis J., Mouton J.W., Meis J.F.G., Bouman B.A., Donnelly P.J., Verweij P.E., Network E. (2001) Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2, 3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol;39:4256-4263.